These results establish gastramide theranostics as an effective approach to CCK2R-targeted therapy, addressing current limitations and providing an improved treatment option for neuroendocrine tumors with substantially enhanced therapeutic outcomes. Here, CCKBR is linked to neuroendocrine neoplasm.